Kelly Elise Dooley MD
Professor of Medicine, Vanderbilt University Medical Center
Join to View Full Profile
1161 21st Avenue South, A2200 MCNNashville, TN 37232
Phone+1 615-322-8972
Dr. Dooley is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Kelly Dooley, MD is a healthcare professional specialized in Infectious Diseases and based in Nashville, TN. Her education included a Fellowship in Infectious Diseases and Residency in Internal Medicine at Johns Hopkins University after graduating from Duke University School of Medicine. Dr. Dooley has experience in emerging infectious diseases and has published in a number of respected journals on topics related to infectious diseases, particularly tuberculosis and HIV. Her work in clinical trials reflects her focus on the study and treatment of tuberculosis.
Education & Training
Johns Hopkins UniversityFellowship, Infectious Disease, 2005 - 2008- Johns Hopkins UniversityResidency, Internal Medicine, 1999 - 2002
Duke University School of MedicineClass of 1999
Certifications & Licensure
OR State Medical License 2002 - Present
TN State Medical License 2022 - 2025
MD State Medical License 2006 - 2022
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Infectious Disease
Clinical Trials
- Safety, Tolerability, and Effect of TMC207 and Efavirenz in Healthy Volunteers Start of enrollment: 2009 Dec 01
- Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers Start of enrollment: 2010 Apr 01
- Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin Start of enrollment: 2012 May 01
- Join now to see all
Publications & Presentations
PubMed
- Development and validation of a time-varying correction factor for QT interval assessment in drug-resistant tuberculosis patients.Thanakorn Vongjarudech, Anne-Gaëlle Dosne, Bart Remmerie, Kelly E Dooley, James C M Brust
International Journal of Antimicrobial Agents. 2025-04-01 - 1 citationsPharmacokinetics and safety of dolutegravir in children receiving rifampicin tuberculosis treatment in South Africa (ORCHID): a prospective cohort study.Anushka Naidoo, Hylke Waalewijn, Kogieleum Naidoo, Marothi Letsoalo, Gabriela Cromhout
The Lancet. HIV. 2025-04-01 - Tuberculosis disease among people with HIV: therapeutic advances.Vidya Mave, Mandar Paradkar, Francesca Conradie, Amita Gupta, Anchalee Avihingsanon
The Lancet. HIV. 2025-03-21
Journal Articles
- State of the Art Review of HIV‐TB Coinfection in Special PopulationsEthel D Weld, Kelly E Dooley, Clinical Pharmacology & Therapeutics
Press Mentions
VUMC’s Kelly Dooley Joins Clinical Pharmacology BoardJanuary 13th, 2025- Johns Hopkins School of Medicine Among Clinical Trial Sites Testing COVID-19 TherapiesNovember 18th, 2020
Johns Hopkins Researchers to Present Latest Findings on TB and HIV at CROI 2019March 7th, 2019- Join now to see all
Grant Support
- Short-course rifapentine for TB prevention for all: clinical pharmacology mattersVANDERBILT UNIVERSITY MEDICAL CENTER2024–2029
- Preclinical Design and Clinical Translation of TB Regimens (PReDicTR) ConsortiumUNIVERSITY OF CALIFORNIA, SAN FRANCISCO2024–2029
- Mentoring Investigators in HIV and Tuberculosis Therapeutics ResearchVANDERBILT UNIVERSITY MEDICAL CENTER2020–2026
- Investigating Multiple PK and PD Relationships for TB-HIV (IMPPRove TB-HIV)VANDERBILT UNIVERSITY MEDICAL CENTER2023–2025
- Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
- Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
- Second Generation InSTIs for the Treatment of HIV-1 in patients with TB co-infection on Rifampicin-based Treatment in KwaZulu Natal, South AfricaCENTRE/AIDS PROGRAMME/RES/SOUTH AFRICA2020–2025
- PK/PD Issues In The Use Of New Therapies For The Treatment Of TuberculosisNational Institute Of Allergy And Infectious Diseases2009–2012
Other Languages
- French
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/kelly-dooley
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
